Lifeboat Foundation

For decades, scientists have been trying to develop therapeutics for people living with Alzheimer’s disease, a progressive neurodegenerative disease that is characterized by cognitive decline. Given the global rise in cases, the stakes are high. A study published in The Lancet Public Health reports that the number of adults living with dementia worldwide is expected to nearly triple, to 153 million in 2050. Alzheimer’s disease is a dominant form of dementia, representing 60 to 70 percent of cases.

Recent approvals by the Food and Drug Administration have focused on medications that shrink the sticky brain deposits of a protein called amyloid beta. The errant growth of this protein is responsible for triggering an increase in tangled threads of another protein called tau and the development of Alzheimer’s disease — at least according to the dominant amyloid cascade hypothesis, which was first proposed in 1991.

Over the past few years, however, data and drugs associated with the hypothesis have been mired in various controversies relating to data integrity, regulatory approval, and drug safety. Nevertheless, the hypothesis still dominates research and drug development. According to Science, in fiscal year 2021 to 2022, the National Institutes of Health spent some $1.6 billion on projects that mention amyloids, about 50 percent of the agency’s overall Alzheimer’s funding. And a close look at the data for recently approved drugs suggests the hypothesis is not wrong, so much as incomplete.

Normandie University researchers have identified critical links between the brain’s inhibitory memory control mechanisms and resilience to post-traumatic stress disorder (PTSD). They examined how the hippocampus and prefrontal memory control processes adapt over time in individuals exposed to trauma, with findings suggesting that the plasticity of these systems supports recovery from PTSD and protects against further neurological damage.

PTSD involves intrusive memories and emotional distress following trauma, with significant attention previously focused on stress vulnerability and hippocampal alterations. The hippocampus, critical for memory processing, is highly susceptible to stress, which can result in structural and functional impairments.

Brain resilience is the process that mitigates stress effects and involves neuroplasticity, or the brain’s ability to reorganize itself. The specific neural mechanisms underlying resilience have remained unclear, though outcomes related to regional brain activation have been observed.

The human working memory (WM) is the cognitive system responsible for the temporary storage and processing of information vital to task completion. In contrast, human long-term memory (LTM) is the system that holds information for prolonged periods of time, organizing acquired knowledge into distinct categories, such as facts, events, skills and habits.

For decades, most psychologists and neuroscientists have viewed these two memory components as separate systems, one tackling short-term and the other long-term tasks, supported by distinct neural processes. Therefore, most studies conducted so far have focused on only one of these systems, instead of exploring the potential connections between working memory and long-term memory processes.

Researchers at the Cedars-Sinai Medical Center and other institutes recently set out to simultaneously investigate the neural underpinnings of both WM and LTM, to determine whether these systems utilize some common mechanisms to store information. Their findings, published in Neuron, suggest that the two systems interact in the hippocampus, with persistent WM activity predicting the formation of LTM.

Link :

Researchers are starting to find patterns in how we sleep that could point to early signs of dementia or Parkinson’s disease.

There are some obvious signs that your loved one could be showing early signs of dementia, which affects almost seven million people in the US.

Continue reading “Scientists discover dream people have that could be an early sign of dementia ‘in almost all cases’” »

Subtle activation of a small subset of neurons in one region of the brain can make male mice resilient to, and even reverse, the detrimental effects of chronic stress. The same is true for female mice, but in a totally different region of the brain.

Researchers at Penn State reported these findings in two studies published in the journal Molecular Psychiatry and said the results could help explain the efficacy, or lack thereof, of certain antidepressant drugs and inform the development of new drugs and therapies.

The team developed a protocol to continuously activate neurons that produce the signaling molecule somatostatin, which helps regulate several biological processes, in specific brain regions in mice. The researchers found that doing so in a region of the brain called the prelimbic cortex made male mice resilient to stress, but failed to do so in female mice.

RNA is the molecule that reads the genetic information stored in DNA. It’s critical for the proper functioning of cells, and in a new study published in Nature Communications, University of California, Irvine scientists have discovered a way of tagging RNA with a glowing bioluminescent molecule that allows them to track RNA in real time as it moves throughout the body. The work promises to help scientists better understand everything from the way viruses propagate to how memories form in the brain.

Researchers unveil how biological sex influences brain aging, revealing genetic, hormonal, and molecular mechanisms behind cognitive resilience and decline.

Back in 2021, a test of cephalopod smarts reinforced how important it is for us humans to not underestimate animal intelligence.

Cuttlefish were given a new version of the marshmallow test, and the results may demonstrate that there’s more going on in their strange little brains than we knew.

Their ability to learn and adapt, the researchers said, could have evolved to give cuttlefish an edge in the cutthroat eat-or-be-eaten marine world they live in.

Think of a future where terminal illnesses can be temporarily halted, allowing time for the development of potential cures.

TimeShift, the world’s first cryopreservation facility, seeks to make the impossible – extending human lifespan – a reality.

Continue reading “World’s first cryopreservation facility could unlock immortality, delay death” »